Global Therapeutic mRNA Patent Landscape Report 2024

Global Therapeutic mRNA Market Size

The global therapeutic mRNA market was valued at USD 13.23 billion in 2023. It is expected to grow at a CAGR of 14.56% during the forecast period of 2024-2032 and attain a market value of USD 32.13 billion by 2032.

The market growth is driven by the increasing adoption of targeted and combination therapies. mRNA technology offers a platform for developing multiple range of therapeutic products. This technology is used to encode proteins which are malfunctioning in specific diseases. The patent landscape of mRNA therapeutics is rapidly evolving as multiple companies have filed their patent applications to protect their inventions.

Patent Landscape Report Coverage

The therapeutic mRNA patent landscape report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for therapeutic mRNA include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within therapeutic mRNA technologies.

The vaccine technology platforms used by the most promising vaccine now include mRNA-based platforms. The COVID-19 pandemic has highlighted the need for the development of the most advanced treatments. Since then, scientists are rushing to develop therapeutics and diagnostics based on mRNA technologies. Hence, patent claims are crucial for the protection of the inventions. This has propelled the number of patent filings and has an impact on the patent landscape significantly.

Therapeutic mRNA Patent Market Outlook

• Therapeutic mRNA technology encompasses a wide range of therapeutic applications, which include cancer immunotherapy, treatments for infectious diseases, genetic disorders, and regenerative medicine. As there is an increasing demand for effective therapeutics, the opportunity for patenting novel mRNA sequences, therapeutic methods, and delivery systems is witnessing a surge.

• Innovations in delivery technologies such as lipid nanoparticles (LNPs), and immune modulation techniques are likely to be patentable as companies are trying to improve the efficacy and safety of mRNA therapies.

• The United States, Europe and China-based companies and universities are the most active applicants of mRNA-based vaccine patents. The top companies include Moderna and CureVac. They have filed patent applications for a wide range of vaccines, signifying their treatment efficiency.

mRNA therapeutics: Introduction

Messenger RNA or mRNA is a type of single-stranded ribonucleic acid that is transcribed from a strand of DNA. It carries the coding information for protein synthesis. The development of mRNA-based therapeutics mainly includes mRNA entrapment, mRNA design, synthesis, pharmacodynamics, pharmacokinetics, and safety evaluation in vivo and in vitro.

The first mRNA COVID-19 vaccine was manufactured by Pfizer–BioNTech, followed by the Moderna COVID-19 vaccine. The successful result of COVID-19 mRNA vaccines has accelerated confidence to utilize these RNA-based technologies. This has led to an increase in investment activities across the pharmaceutical industry. As more therapies move through clinical trials; the patent filings are expected to increase.

Therapeutic mRNA Industry Growth Drivers

Clinical Trials Success and Increasing Adoption is Expected to Augment the Patent Industry Growth

The mRNA-based therapy is expected to be useful in multiple treatments related to infectious diseases, cancer, cardiovascular disease, metabolic genetic diseases, and cerebrovascular diseases, among others. These drugs offer the advantages of low side effects and higher efficiency.

A recent clinical trial study reported the successful delivery of a target gene to the heart using a CD5 antibody conjugated to LNP-mRNA. The gene delivery efficiency increased from 7% to 83% when using the CD5-LNP-mRNA. The mRNA-based drugs have huge potential as clinical treatments. Therefore, it is essential to develop strong patent portfolios to protect innovative therapies.

Advancements in Delivery Platform is Expected to Propel Therapeutic mRNA Patent Industry Growth

The continuous developments in mRNA synthesis and delivery technologies expand the patent landscape. The innovative developments in delivery platforms like lipid nanoparticles (LNPs), enhance the efficacy and safety of mRNA therapies. The development of mRNA technology-based COVID-19 vaccines was facilitated using lipid nanoparticle (LNP) vectors. It can deliver mRNA cargo to host cells, and this trigger an appropriate immune response.

LNP has several other advantages over other delivery technologies like the ability to carry multiple mRNAs in one formulation, being minimally immunogenic and easy to scale up.

Therapeutic mRNA Patent Segmentation

The report will cover the following sections in detail:

Analysis by Design

• Self-Amplifying mRNA

• Conventional Non-Amplifying mRNA

Analysis by Route of Administration

• Intravenous

• Intramuscular

• Others

Analysis by Indication

• Oncology

• Infectious Diseases

• Autoimmune Diseases

• Others

Therapeutic mRNA Patent Segmentation Analysis

The breakup based on design includes self-amplifying mRNA and conventional non-amplifying mRNA. Therapeutic mRNA investigations have been conducted with the chosen patent families labelled based on the platforms to which they pertain.

For instance, self-amplifying RNA (saRNA) vaccines utilize a self-replicating RNA platform to produce immune responses in the body. The RNA vaccines aim to stimulate the immune system to defend against specific pathogens. It uses genetic material, specifically, messenger RNA, instead of using inactivated viruses, to and instruct cells to produce a protein.
Detailed technological data will be provided for all specified segments classified in this report.

Therapeutic mRNA Patent Jurisdiction Analysis

The United States is one of the leading jurisdictions for oncology immunotherapy patents, having around 277,000+ patents. The presence of major pharmaceutical companies, well-established healthcare infrastructure, and advanced research and development activities contributes to the patent landscape significantly.

Patent Profile of Key Companies

Among the players with therapeutic mRNA patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

Pfizer, Inc.

Pfizer, Inc. founded in 1849 and headquartered in the United States is a global pharmaceutical company engaged in the development of medicines and vaccines in multiple therapeutic areas including cancer, cardiovascular diseases, and neurology among others. Pfizer is developing innovation in mRNA-based technologies in the infectious disease arena with vaccine development programs for flu and shingles, along with respiratory combination vaccines.

Novartis AG

Novartis AG, founded in 1996, and headquartered in Switzerland, is a global pharmaceutical company. It is engaged in the development of therapies in multiple areas including oncology, respiratory diseases, neurological disorders, and diabetes among others. The company is developing innovative RNA-targeting therapies which have the potential to lower cholesterol levels and reduce the risk of heart disease. Novartis has filed numerous patents to protect its IPs within mRNA technologies.

Other companies include Genentech Inc., Amgen Inc., and Regeneron Pharma among others.

Reasons to Purchase this Report

The therapeutic mRNA patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by -

• Competitive Advantage: The landscape reveals the market leaders, potential partners and innovators and also makes it understandable which companies have important patents in this field of therapeutic mRNA.

• Innovation Insights: The patent analysis reveals new innovations and technologies in the therapeutic mRNA industry.

• Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry.

• Risk Assessment: In technology-intensive fields such as therapeutic mRNA, risks of IP infringement are common. Analyzing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.

Key Questions Answered in the Therapeutic mRNA Patent Landscape Report

• Who are the key players in the therapeutic mRNA patent landscape?
• How is the patent portfolio distributed geographically?
• What are the emerging trends in therapeutic mRNA patents?
• How has the patent landscape evolved over time?
• What are the strategic insights for market players and investors?
• What is the technological focus of patents in the therapeutic mRNA industry?
• How do patent strategies impact competitive advantage?
• What are the implications of patent filings in therapeutic mRNA?
• What are the challenges and opportunities in the therapeutic mRNA patent landscape?
• What are the regulatory and legal considerations?
• What technological innovations have recently emerged in therapeutic mRNA?

Related Reports

Cancer Immunotherapy Market

Immunotherapy Drugs Market

Monoclonal Antibodies Market

Cancer Vaccines Market